Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Income from Continuing Operations (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Income from Continuing Operations for 16 consecutive years, with 1690000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 88.53% year-over-year to 1690000.0, compared with a TTM value of 27110000.0 through Dec 2025, up 51.68%, and an annual FY2025 reading of 27110000.0, up 51.68% over the prior year.
  • Income from Continuing Operations was 1690000.0 for Q4 2025 at Amicus Therapeutics, down from 17306000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 17306000.0 in Q3 2025 and bottomed at 85260000.0 in Q1 2022.
  • Average Income from Continuing Operations over 5 years is 36091400.0, with a median of 38537500.0 recorded in 2023.
  • Peak annual rise in Income from Continuing Operations hit 357.19% in 2025, while the deepest fall reached 88.53% in 2025.
  • Year by year, Income from Continuing Operations stood at 83277000.0 in 2021, then skyrocketed by 32.92% to 55865000.0 in 2022, then soared by 39.42% to 33843000.0 in 2023, then soared by 143.55% to 14739000.0 in 2024, then crashed by 88.53% to 1690000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for FOLD at 1690000.0 in Q4 2025, 17306000.0 in Q3 2025, and 24420000.0 in Q2 2025.